These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8154021)

  • 1. Prolongation of in vivo mouse islet allograft survival by modulation of MHC class I antigen.
    Osorio RW; Ascher NL; Stock PG
    Transplantation; 1994 Mar; 57(6):783-8. PubMed ID: 8154021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A major role for host MHC class I antigen presentation for promoting islet allograft survival.
    Beilke J; Johnson Z; Kuhl N; Gill RG
    Transplant Proc; 2004 May; 36(4):1173-4. PubMed ID: 15194406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major histocompatibility complex class I deficiency prolongs islet allograft survival.
    Osorio RW; Ascher NL; Jaenisch R; Freise CE; Roberts JP; Stock PG
    Diabetes; 1993 Oct; 42(10):1520-7. PubMed ID: 8375593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of intra-islet endothelial cells in islet allo-immunity.
    Bharat A; Saini D; Benshoff N; Goodman J; Desai NM; Chapman WC; Mohanakumar T
    Transplantation; 2007 Nov; 84(10):1316-23. PubMed ID: 18049117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T cells maintain peripheral tolerance to islet allografts induced by intrathymic injection of MHC class I allopeptides.
    Saborio DV; Chowdhury NC; Jin MX; Chandraker A; Sayegh MH; Oluwole SF
    Cell Transplant; 1999; 8(4):375-81. PubMed ID: 10478717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organ donor or graft pretreatment to prolong allograft survival: lessons learned in the murine model.
    Pollak R; Blanchard JM
    Transplantation; 2000 Jun; 69(11):2432-9. PubMed ID: 10868654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of islet allograft survival in mice treated with MHC class I specific F(ab')2 alloantibody.
    Osorio RW; Ascher NL; Melzer JS; Stock PG
    Transplant Proc; 1994 Apr; 26(2):749. PubMed ID: 8171642
    [No Abstract]   [Full Text] [Related]  

  • 8. Indefinite survival of MHC class I-deficient murine pancreatic islet allografts.
    Markmann JF; Bassiri H; Desai NM; Odorico JS; Kim JI; Koller BH; Smithies O; Barker CF
    Transplantation; 1992 Dec; 54(6):1085-9. PubMed ID: 1465773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Awareness of donor alloantigens in antiadhesion therapy induces antigen-specific unresponsiveness to islet allografts.
    Nishihara M; Gotoh M; Ohzato H; Ohta Y; Luo Z; Dono K; Umeshita K; Sakon M; Monden M; Yagita H; Okumura K; Miyasaka M
    Transplantation; 1997 Oct; 64(7):965-70. PubMed ID: 9381542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
    Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
    J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer T cell facilitated engraftment of rat skin but not islet xenografts in mice.
    Gordon EJ; Kelkar V
    Xenotransplantation; 2009; 16(3):135-44. PubMed ID: 19566653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of xenograft rejection by masking donor HLA class I antigens.
    Faustman D; Coe C
    Science; 1991 Jun; 252(5013):1700-2. PubMed ID: 1710828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The degree of phylogenetic disparity of islet grafts dictates the reliance on indirect CD4 T-cell antigen recognition for rejection.
    Rayat GR; Johnson ZA; Beilke JN; Korbutt GS; Rajotte RV; Gill RG
    Diabetes; 2003 Jun; 52(6):1433-40. PubMed ID: 12765954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged survival of class I deficient mouse islet allografts but not xenografts.
    Markmann JF; Desai NM; Bassiri H; Kim JI; Barker CF
    Transplant Proc; 1994 Apr; 26(2):748. PubMed ID: 8171641
    [No Abstract]   [Full Text] [Related]  

  • 15. Anergic T cells generated in vitro suppress rejection response to islet allografts.
    Luo Z; Gotoh M; Grochowiecki T; Tanaka T; Kimura F; Kawashima H; Yagita H; Okumura K; Miyasaka M
    Transplantation; 2000 May; 69(10):2144-8. PubMed ID: 10852614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of transplant rejection by pretreatment of xenogeneic pancreatic islet cells with anti-ICAM-1 antibodies.
    Zeng Y; Gage A; Montag A; Rothlein R; Thistlethwaite JR; Bluestone JA
    Transplantation; 1994 Sep; 58(6):681-9. PubMed ID: 7940687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rat pancreatic islet pretreatment with anti-MHC class II monoclonal antibodies and culture: in vitro MLIC test response does not predict islet allograft survival.
    Bretzel RG; Flesch BK; Brennenstuhl G; Greiner I; Hering BJ; Woehrle M; Federlin K
    Acta Diabetol; 1993; 30(1):49-56. PubMed ID: 8329731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of donor beta 2-microglobulin-deficient transgenic mouse liver cells for isografts, allografts, and xenografts.
    Li X; Faustman D
    Transplantation; 1993 Apr; 55(4):940-6. PubMed ID: 8475570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade.
    Makhlouf L; Kishimoto K; Smith RN; Abdi R; Koulmanda M; Winn HJ; Auchincloss H; Sayegh MH
    Diabetes; 2002 Nov; 51(11):3202-10. PubMed ID: 12401711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically engineered grafts to study xenoimmunity: a role for indirect antigen presentation in the destruction of major histocompatibility complex antigen deficient xenografts.
    Markmann JF; Campos L; Bhandoola A; Kim JI; Desai NM; Bassiri H; Claytor BR; Barker CF
    Surgery; 1994 Aug; 116(2):242-8; discussion 248-9. PubMed ID: 8047991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.